Triple threat: new combo aims to stop lung cancer in its tracks
NCT ID NCT03141359
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a three-step approach for stage II or III non-small cell lung cancer. First, the main tumor gets a high-dose radiation blast (SBRT). Then, the chest lymph nodes receive standard radiation plus chemotherapy. Finally, patients get an immunotherapy drug (durvalumab) to help prevent the cancer from coming back. The study enrolled 61 people and is now following them to see how many are alive without cancer progression after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (immunotherapy), Carboplatin, Paclitaxel, Cisplatin, Etoposide (chemotherapy), and radiation therapy (SBRT, IMRT)
What this could lead to
If successful, this combination approach could improve the chance of keeping lung cancer from growing or returning for at least a year.
What could go wrong
This is a small, single-arm Phase II trial, so results may not apply broadly. Side effects from radiation, chemotherapy, and immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States